mergers & acquisitions
Taiho Pharmaceutical Acquires Cullinan Pearl, Regaining Rights to EGFR Inhibitor
Taiho licensed the drug to Cullinan in 2019 but has now acquired Cullinan subsidiary Cullinan Pearl to resume codevelopment and commercialization of the program.
Tempus Acquires Highline Sciences
Oncology-focused contract research organization Highline Sciences will help Tempus vertically integrate clinical trial services.
Calibre Scientific Acquires Sequencing Sample Prep Reagent Firm BrightBox Quantitation
The deal follows Calibre Scientific's recent acquisition of French life science reagent and instrument distributor AmpliTech.
Exact Sciences Projects up to $475M in Q4 Revenues, Acquires Testing Lab, Inks Licensing Deal
The approximately 2 percent increase over Q4 2020 results beat analysts' expectations, and the acquisition news heralds market expansion into hereditary cancer testing.
Predictive Oncology Acquires 3D Tumor Model Developer ZPredicta
Predictive Oncology will integrate information from ZPredicta's 3D tumor models into its AI-based platforms and inform precision drug development.
Nov 22, 2021
Cancer Dx Firms ACT Genomics, Sanomics Merge
Jul 27, 2021
Kiromic BioPharma Acquires InSilico Solutions
Jun 23, 2021
Dante Labs Acquires Cambridge Cancer Genomics
Jun 1, 2021
Veracyte to Acquire HalioDx for €260M
Mar 24, 2021
NeoGenomics Acquires Trapelo Health in $65M Deal
Mar 17, 2021
Mar 4, 2021